| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/11/2023 | Outperform | Evercore ISI | |
| 10/10/2023 | $29.00 | Buy | Truist |
| 10/10/2023 | $35.00 | Buy | Jefferies |
| 10/10/2023 | $30.00 | Overweight | JP Morgan |
| 10/6/2023 | Outperform | William Blair |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Evercore ISI initiated coverage of RayzeBio with a rating of Outperform
Truist initiated coverage of RayzeBio with a rating of Buy and set a new price target of $29.00
Jefferies initiated coverage of RayzeBio with a rating of Buy and set a new price target of $35.00
JP Morgan initiated coverage of RayzeBio with a rating of Overweight and set a new price target of $30.00
William Blair initiated coverage of RayzeBio with a rating of Outperform
15-12G - RayzeBio, Inc. (0001825367) (Filer)
S-8 POS - RayzeBio, Inc. (0001825367) (Filer)
25-NSE - RayzeBio, Inc. (0001825367) (Subject)
SC 14D9/A - RayzeBio, Inc. (0001825367) (Subject)
SC TO-T/A - RayzeBio, Inc. (0001825367) (Subject)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
Fastest customizable press release news feed in the world
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo
Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "By strengthening and further diversifying our oncology pipeline bey
Bristol Myers Squibb (NYSE:BMY) today announced that its previously announced tender offer (the "Offer") to acquire all of the outstanding shares of RayzeBio, Inc. (NASDAQ:RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the "Expiration Time"). Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiration Time, approximately 53,052,499 shares of RazyeBio common stock were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 86% of the issued and outstanding shares of RayzeBio common stock at th
Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb's previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. The expiration of the waiting period occurred at 11:59 p.m. EST on February 9, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240211117969/en/ Expiration of the waiting period under the HSR Act satisfies one of th
Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State of the Art Radiopharmaceutical Manufacturing Capabilities PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which
Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State-of-the-Art Radiopharmaceutical Manufacturing Capabilities Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per shar
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today reported financial results for the third quarter ended September 30, 2023 and provided an update on key corporate initiatives. "We have made significant progress in 2023 and achieved several clinical, discovery and corporate milestones as we continue to lead innovation in developing targeted radiopharmaceuticals for the benefit of patients with cancer," said Ken Song, M.D., President and CEO of RayzeBio. "Our lead asset, RYZ101, is the first Actinium-225 based treatment in a Phase 3 clinical trial.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of the Company's management team will participate in the following investor conferences in November 2023: Truist Securities BioPharma Symposium: Panel discussion on Wednesday, November 8 at 10:45 a.m. ET in New York.Jefferies London Healthcare Conference: Presentation on Wednesday, November 15 at 12:00 p.m. GMT (7:00 a.m. ET) in London, England.Evercore ISI HealthCONx Conference: Fireside chat on Thursday, November 30 at 10:00 a.m. ET in Miami. RayzeBio will also be participati
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Tim Van Hauwermeiren to its board of directors. As co-founder and CEO of argenx, Tim has built a reputation for his strong execution and innovation, leading argenx from early-stage development into a global immunology company. "RayzeBio has the potential to transform the oncology treatment landscape through targeted radiopharmaceuticals. I see a lot of parallels between RayzeBio and argenx and look forward to leveraging my experience to help RayzeBio unlock the full pote
Live Leadership Updates
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Tim Van Hauwermeiren to its board of directors. As co-founder and CEO of argenx, Tim has built a reputation for his strong execution and innovation, leading argenx from early-stage development into a global immunology company. "RayzeBio has the potential to transform the oncology treatment landscape through targeted radiopharmaceuticals. I see a lot of parallels between RayzeBio and argenx and look forward to leveraging my experience to help RayzeBio unlock the full pote
This live feed shows all institutional transactions in real time.
SC 13G/A - RayzeBio, Inc. (0001825367) (Subject)
Live finance-specific insights
Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "By strengthening and further diversifying our oncology pipeline bey
Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State of the Art Radiopharmaceutical Manufacturing Capabilities PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which
Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State-of-the-Art Radiopharmaceutical Manufacturing Capabilities Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per shar